サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1511835

米国のエピジェネティクス市場規模、シェア、動向分析レポート：製品別、技術別、用途別、最終用途別、セグメント予測、2024年～2030年

U.S. Epigenetics Market Size, Share & Trends Analysis Report By Product (Reagents, Kits), By Technology (DNA Methylation, Histone Methylation), By Application (Oncology, Non-oncology), By End-use, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
米国のエピジェネティクス市場規模、シェア、動向分析レポート：製品別、技術別、用途別、最終用途別、セグメント予測、2024年～2030年
出版日: 2024年06月11日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国のエピジェネティクス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国のエピジェネティクス市場規模は、2024年から2030年にかけて14.5%のCAGRで成長し、2030年までに131億米ドルに達すると予測されています。

がんや慢性疾患の有病率の増加、エピジェネティクス研究や技術の進歩、生物医学研究への投資の増加、個別化医療の採用の増加は、予測期間にわたってエピジェネティクスの需要を増加させると予測されています。

COVID-19パンデミックは市場に好影響を与えました。パンデミックは、ウイルスとその人体への影響の理解に関連する研究活動の大幅な増加に拍車をかけた。これには、COVID-19が遺伝子発現や免疫応答にどのような影響を及ぼすかを研究するエピジェネティック研究も含まれました。その結果、COVID-19に関連するエピジェネティック研究に対する政府・民間両部門からの資金提供が増加しました。

さらに、企業はエピジェネティクス製品の開発への投資を増やしました。多くのバイオテクノロジー企業や製薬企業が、疾患メカニズムや治療反応におけるエピジェネティクスの役割を探るために研究開発予算を増やしました。このような資金の流入は、この分野における発見と革新のペースを加速させています。外部資金から医療システムへの国内投資への移行は、革新的な解決策の必要性を強調しています。ヘルスケアの進歩に組み込まれたエピジェネティクスは、健康転帰を改善するソリューションを提供することで、局面を一変させると予測されています。

しかし、市場の成長は熟練した専門家の不足によって制約されています。エピジェネティクスの複雑な性質は、遺伝学、分子生物学、データ分析の深い理解を要求します。この不足は、研究と技術の進歩を減速させ、洞察のために重要な複雑なデータ分析を妨げ、臨床への移行を遅らせ、教育イニシアチブを妨げる可能性があります。これは市場の成長をある程度妨げると予想されます。

米国のエピジェネティクス市場レポートハイライト

  • 試薬が製品セグメントを支配し、2023年の収益シェアは32.5%で最大。試薬は汎用性が高く、基礎研究、臨床診断、医薬品開発など幅広い用途で使用されています。一方、サービスは予測期間中に最も速いCAGRで成長すると予測されています。
  • 技術分野では、DNAメチル化が2023年に最大の市場シェアを占めました。DNAメチル化は、遺伝子発現の制御に重要な役割を果たす重要なエピジェネティック修飾の一つです。しかし一方で、ヒストンアセチル化は予測期間中に最も速いCAGRで成長すると予想されています。
  • 用途別では、がん領域が2023年に最大の市場シェアを占めました。これは、がんの有病率の増加に起因しています。しかし一方で、非腫瘍学は予測期間中に最も速いCAGRで成長する見込みです。
  • 最終用途に基づくと、学術研究が2023年に最大の収益シェアでセグメントを支配しました。これは、学術機関で実施される臨床研究の数が増加していることと、研究活動に対する資金が増加していることに起因しています。一方、臨床研究は予測期間中に最も速いCAGRで成長すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 米国のエピジェネティクス市場：製品ビジネス分析

  • セグメントダッシュボード
  • 米国のエピジェネティクス市場：製品変動分析
  • 米国のエピジェネティクス市場規模と動向分析、製品別、2018～2030年
  • 試薬
  • キット
  • 機器
  • 酵素
  • サービス

第5章 米国のエピジェネティクス市場：技術のビジネス分析

  • セグメントダッシュボード
  • 米国のエピジェネティクス市場：技術変動分析
  • 米国のエピジェネティクス合成市場規模と動向分析、技術別、2018～2030年
  • DNAメチル化
  • ヒストンのメチル化
  • ヒストンのアセチル化
  • 大きな非コードRNA
  • マイクロRNAの修飾
  • クロマチン構造

第6章 米国のエピジェネティクス市場：用途のビジネス分析

  • セグメントダッシュボード
  • 米国のエピジェネティクス市場：用途変動分析
  • 米国のエピジェネティクス合成市場規模と動向分析、用途別、2018～2030年
  • 腫瘍学
  • 非腫瘍学

第7章 米国のエピジェネティクス市場：最終用途のビジネス分析

  • セグメントダッシュボード
  • 米国のエピジェネティクス市場：最終用途変動分析
  • 米国のエピジェネティクス市場規模と動向分析、最終用途別、2018～2030年
  • 学術調査
  • 臨床調査
  • 病院・クリニック
  • 製薬・バイオテクノロジー企業
  • その他

第8章 競合情勢

  • 参入企業
  • 戦略マッピング
  • 企業市況分析、2023年
  • 参入企業の概要
    • Roche Diagnostics
    • Thermo Fisher Scientific, Inc.
    • Danaher
    • Eisai Co. Ltd.
    • Novartis AG
    • Element Biosciences, Inc.
    • Dovetail Genomics LLC.
    • Illumina, Inc.
    • Promega Corporation.
    • Abcam plc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. epigenetics market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. epigenetics market, by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S. epigenetics market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. epigenetics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Participant's overview
  • Table 8 Financial performance
  • Table 9 Key companies undergoing expansions
  • Table 10 Key companies undergoing acquisitions
  • Table 11 Key companies undergoing collaborations
  • Table 12 Key companies launching new products/services
  • Table 13 Key companies undertaking other strategies

List of Figures

  • Fig. 1 U.S. epigenetics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. epigenetics market driver analysis
  • Fig. 14 U.S. epigenetics market restraint analysis
  • Fig. 15 U.S. epigenetics market: Porter's analysis
  • Fig. 16 U.S. epigenetics market: Product outlook key takeaways
  • Fig. 17 U.S. epigenetics market: Product movement analysis
  • Fig. 18 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 ChIP sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Whole genomic amplification kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Bisulfite conversion kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 RNA sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. epigenetics market: Technology movement analysis
  • Fig. 26 U.S. epigenetics market: Technology outlook and key takeaways
  • Fig. 27 DNA methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Histone methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Histone acetylation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Large non - coding RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 MicroRNA modification market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Chromatin structures market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. epigenetics market: Application movement analysis
  • Fig. 34 U.S. epigenetics market: Application outlook and key takeaways
  • Fig. 35 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Liquid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Non-oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Inflammatory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Metabolic diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. epigenetics market End-use outlook key takeaways
  • Fig. 45 U.S. epigenetics market: End-use movement analysis
  • Fig. 46 Academic research market estimates and forecast, 2018 - 2030 (USD Million))
  • Fig. 47 Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Key company categorization
  • Fig. 52 Company market positioning
  • Fig. 53 Market participant categorization
  • Fig. 54 Strategy framework
目次
Product Code: GVR-4-68040-301-9

U.S. Epigenetics Market Growth & Trends:

The U.S. epigenetics market size is anticipated to reach USD 13.10 billion by 2030, growing at a CAGR of 14.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of cancer and chronic diseases, advancements in epigenetic research and technologies, rising investment in biomedical research, and increasing adoption of personalized medicine are anticipated to increase the demand for epigenetics over the forecast period.

The COVID-19 pandemic has had a positive impact on the market. The pandemic spurred a significant increase in research activities related to understanding the virus and its effects on human health. This included epigenetic research to study how COVID-19 affects gene expression and immune responses. Consequently, there was increased funding from both government and private sectors for epigenetic studies related to COVID-19.

Moreover, companies have increased investments in the development of epigenetics products. Many biotechnology and pharmaceutical companies have increased their research and development budgets to explore the role of epigenetics in disease mechanisms and treatment responses. This influx of funding has accelerated the pace of discoveries and innovations in the field. The transition from external funding to domestic investment in health systems underscores the need for innovative solutions. Epigenetics, embedded in advancing healthcare, is projected to transform the phase by offering solutions for improving health outcomes.

However, the growth of the market is constrained by a scarcity of skilled professionals. The complex nature of epigenetics demands a deep understanding of genetics, molecular biology, and data analysis. This shortage can decelerate research & technological progress, hinder complex data analysis crucial for insights, slow clinical translation, and hamper educational initiatives. This is anticipated to hamper the growth of the market to a certain extent.

U.S. Epigenetics Market Report Highlights:

  • Reagents dominated the product segment with the largest revenue share of 32.5% in 2023. Reagents are versatile and used in a wide range of applications, including basic research, clinical diagnostics, and drug development. On the other hand, services are expected to grow at the fastest CAGR over the forecast period.
  • The DNA methylation held the largest market share in 2023 for the technology segment. DNA methylation is one of the key epigenetic modifications that plays a vital role in regulating gene expression. However, on the other hand, histone acetylation is expected to grow at the fastest CAGR over the forecast period.
  • The oncology held the largest market share in 2023 for the application segment. This is attributed to the growing prevalence of cancer. However, on the other hand, non-oncology is expected to grow at the fastest CAGR over the forecast period.
  • Based on end-use, academic research dominated the segment with the largest revenue share in 2023. This is attributed to the increasing number of clinical studies which are being conducted in academic institutes and the growing funding for research activities. On the other hand, clinical research is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. End-use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Rising geriatric patient population
      • 3.2.1.3. Increasing government initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of standardization in epigenetics-based diagnostics
      • 3.2.2.2. Lack of skilled professionals
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Epigenetics Market: Product Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Epigenetics Market Product Movement Analysis
  • 4.3. U.S. Epigenetics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Reagents
    • 4.4.1. Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5. Kits
    • 4.5.1. Kits market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2. ChIP Sequencing Kit
      • 4.5.2.1. ChIP sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3. Whole Genomic Amplification Kit
      • 4.5.3.1. Whole genomic amplification kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.4. Bisulfite Conversion Kit
      • 4.5.4.1. Bisulfite conversion kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.5. RNA Sequencing Kit
      • 4.5.5.1. RNA sequencing kit market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.6. Others
      • 4.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.6. Instruments
    • 4.6.1. Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.7. Enzymes
    • 4.7.1. Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.8. Services
    • 4.8.1. Services market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Epigenetics Market: Technology Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Epigenetics Market Technology Movement Analysis
  • 5.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 5.4. DNA Methylation
    • 5.4.1. DNA methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Histone Methylation
    • 5.5.1. Histone methylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Histone Acetylation
    • 5.6.1. Histone acetylation market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. Large Non - coding RNA
    • 5.7.1. Large non - coding RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.8. MicroRNA Modification
    • 5.8.1. MicroRNA modification market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.9. Chromatin Structures
    • 5.9.1. Chromatin structures market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Epigenetics Market: Application Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Epigenetics Market Application Movement Analysis
  • 6.3. U.S. Epigenetics Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.2. Solid Tumors
      • 6.4.2.1. Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.3. Liquid Tumors
      • 6.4.3.1. Liquid tumors market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Non-oncology
    • 6.5.1. Non-oncology market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2. Inflammatory Diseases
      • 6.5.2.1. Inflammatory diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.3. Metabolic Diseases
      • 6.5.3.1. Metabolic diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.4. Infectious Diseases
      • 6.5.4.1. Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.5. Cardiovascular Diseases
      • 6.5.5.1. Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.6. Others
      • 6.5.6.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. U.S. Epigenetics Market: End-use Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Epigenetics Market End-use Movement Analysis
  • 7.3. U.S. Epigenetics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 7.4. Academic Research
    • 7.4.1. Academic research market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Clinical Research
    • 7.5.1. Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6. Hospitals & Clinics
    • 7.6.1. Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7. Pharmaceutical & Biotechnology Companies
    • 7.7.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8. Others
    • 7.8.1. Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Participant's Overview
    • 8.4.1. Roche Diagnostics
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product & service benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Thermo Fisher Scientific, Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product & service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Danaher
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product & service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Eisai Co. Ltd.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product & service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product & service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Element Biosciences, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product & service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Dovetail Genomics LLC.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product & service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Illumina, Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product & service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Promega Corporation.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product & service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Abcam plc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product & service benchmarking
      • 8.4.10.4. Strategic initiatives